Captrust Financial Advisors Acquires 9,087 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Captrust Financial Advisors lifted its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 89.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,261 shares of the biotechnology company’s stock after acquiring an additional 9,087 shares during the period. Captrust Financial Advisors’ holdings in Aldeyra Therapeutics were worth $104,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. SG Americas Securities LLC purchased a new position in Aldeyra Therapeutics during the second quarter worth about $38,000. Hennion & Walsh Asset Management Inc. boosted its holdings in Aldeyra Therapeutics by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 88,122 shares of the biotechnology company’s stock worth $292,000 after purchasing an additional 6,944 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Aldeyra Therapeutics by 21.7% during the second quarter. Bank of New York Mellon Corp now owns 195,722 shares of the biotechnology company’s stock worth $648,000 after purchasing an additional 34,885 shares during the last quarter. Panagora Asset Management Inc. purchased a new position in Aldeyra Therapeutics during the second quarter worth about $200,000. Finally, Rhumbline Advisers boosted its holdings in Aldeyra Therapeutics by 20.1% during the second quarter. Rhumbline Advisers now owns 76,981 shares of the biotechnology company’s stock worth $255,000 after purchasing an additional 12,907 shares during the last quarter. 59.71% of the stock is owned by institutional investors.

Aldeyra Therapeutics Price Performance

ALDX opened at $5.06 on Tuesday. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. Aldeyra Therapeutics, Inc has a twelve month low of $2.71 and a twelve month high of $6.55. The company’s 50-day moving average price is $5.15 and its two-hundred day moving average price is $4.74.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, meeting analysts’ consensus estimates of ($0.25). As a group, equities analysts predict that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.